Press Releases

Press Releases

    Date Title View
    05/23/23
    Summary ToggleHorizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
    PDF Version
    05/16/23
    Summary ToggleHorizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
    PDF Version
    05/10/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    PDF Version
    05/09/23
    Summary ToggleHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
    PDF Version
    05/04/23
    Summary ToggleHorizon Therapeutics plc (“Horizon”) - Rule 2.12 Announcement
    PDF Version
    05/03/23
    Summary ToggleHorizon Therapeutics plc Reports First-Quarter 2023 Financial Results
    05/02/23
    Summary ToggleHorizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
    PDF Version
    05/02/23
    Summary ToggleHorizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
    PDF Version
    05/01/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    05/01/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    Displaying 1 - 10 of 46 results